ATE177756T1 - Neue peptide aus einem autoantigen zur verwendung bei immuntherapie von autoimmunkrankheit - Google Patents

Neue peptide aus einem autoantigen zur verwendung bei immuntherapie von autoimmunkrankheit

Info

Publication number
ATE177756T1
ATE177756T1 AT95937008T AT95937008T ATE177756T1 AT E177756 T1 ATE177756 T1 AT E177756T1 AT 95937008 T AT95937008 T AT 95937008T AT 95937008 T AT95937008 T AT 95937008T AT E177756 T1 ATE177756 T1 AT E177756T1
Authority
AT
Austria
Prior art keywords
peptides
autoantigen
seq
pct
sec
Prior art date
Application number
AT95937008T
Other languages
English (en)
Inventor
Anna Maria Helena Boots
Gijsbertus Francisc Verheijden
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE177756T1 publication Critical patent/ATE177756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95937008T 1994-10-27 1995-10-25 Neue peptide aus einem autoantigen zur verwendung bei immuntherapie von autoimmunkrankheit ATE177756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP95200886 1995-04-07

Publications (1)

Publication Number Publication Date
ATE177756T1 true ATE177756T1 (de) 1999-04-15

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937008T ATE177756T1 (de) 1994-10-27 1995-10-25 Neue peptide aus einem autoantigen zur verwendung bei immuntherapie von autoimmunkrankheit

Country Status (23)

Country Link
US (1) US5736507A (de)
EP (1) EP0733065B1 (de)
JP (1) JP3755894B2 (de)
KR (1) KR100485979B1 (de)
CN (1) CN1161379C (de)
AT (1) ATE177756T1 (de)
AU (1) AU696827B2 (de)
BR (1) BR9506377A (de)
CA (1) CA2173874A1 (de)
DE (1) DE69508380T2 (de)
DK (1) DK0733065T3 (de)
ES (1) ES2130672T3 (de)
FI (1) FI118472B (de)
GR (1) GR3030296T3 (de)
HU (1) HU218027B (de)
IL (1) IL115744A (de)
MX (1) MX9602495A (de)
NO (1) NO316703B1 (de)
NZ (1) NZ295659A (de)
PL (1) PL183761B1 (de)
RU (1) RU2178797C2 (de)
TR (1) TR199501326A2 (de)
WO (1) WO1996013517A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
TW575583B (en) 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
RU2196606C2 (ru) * 1996-09-18 2003-01-20 Зетесис С.п.А. Применение белков в качестве агентов против аутоиммунных заболеваний
EP0947524A1 (de) * 1998-03-30 1999-10-06 Upither B.V. Neue Peptide zur Behandlung von Autoimmunkrankheiten
TR200100175T2 (tr) * 1998-07-23 2001-09-21 Akzo Nobel N.V. Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
JP2002521344A (ja) * 1998-07-23 2002-07-16 アクゾ・ノベル・エヌ・ベー 免疫疾患におけるＨＣｇｐ−３９の使用
PL201172B1 (pl) * 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
KR20020047245A (ko) * 1999-10-18 2002-06-21 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 면역요법에 사용하기 위한 수정 펩티드 및 펩티드모방체
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
CA2454342A1 (en) * 2001-07-24 2003-02-06 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
EP1729805A4 (de) * 2004-02-25 2008-11-26 Medimmune Inc Verfahren und zusammensetzungen im zusammenhang mit chitinasen und chitinase-artigen molekülen und modulierung von osteoklasten
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
US8821887B2 (en) * 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
EP2153841B2 (de) 2008-08-15 2015-11-11 Circassia Limited Impfstoff beinhaltend Amb a 1 Peptide zur Behandlung von Traubenkraut-Allergie
SI2393830T1 (sl) 2009-02-05 2015-04-30 Circassia Limited Travni peptidi za cepivo
ES2600932T3 (es) * 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CN109415741A (zh) 2016-05-03 2019-03-01 Sqz生物技术公司 细胞内递送生物分子以诱导耐受性

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
GB9125024D0 (en) * 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
WO1993015750A1 (en) * 1992-02-10 1993-08-19 Haynes Barton F Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens
CA2144044A1 (en) * 1992-09-14 1994-03-31 The Brigham And Women's Hospital Reagents and methods for treating rheumatoid arthritis
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
CN1168677A (zh) 1997-12-24
PL315198A1 (en) 1996-10-14
HK1002012A1 (en) 1998-07-24
NO962695L (no) 1996-06-26
DE69508380T2 (de) 1999-09-09
PL183761B1 (pl) 2002-07-31
NO316703B1 (no) 2004-04-13
HU9601401D0 (en) 1996-07-29
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
CA2173874A1 (en) 1996-05-09
JPH09507861A (ja) 1997-08-12
GR3030296T3 (en) 1999-09-30
IL115744A (en) 2000-07-16
BR9506377A (pt) 1997-09-16
AU3925295A (en) 1996-05-23
MX9602495A (es) 1997-05-31
TR199501326A2 (tr) 1996-06-21
DE69508380D1 (de) 1999-04-22
DK0733065T3 (da) 1999-10-11
NZ295659A (en) 1998-02-26
HU218027B (hu) 2000-05-28
JP3755894B2 (ja) 2006-03-15
US5736507A (en) 1998-04-07
EP0733065B1 (de) 1999-03-17
RU2178797C2 (ru) 2002-01-27
KR100485979B1 (ko) 2006-01-27
KR960705848A (ko) 1996-11-08
ES2130672T3 (es) 1999-07-01
FI962619A0 (fi) 1996-06-25
FI962619L (fi) 1996-06-25
EP0733065A1 (de) 1996-09-25
CN1161379C (zh) 2004-08-11
FI118472B (fi) 2007-11-30
NO962695D0 (no) 1996-06-26
WO1996013517A1 (en) 1996-05-09
AU696827B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
DE69508380D1 (de) Neue peptide aus einem autoantigen zur verwendung bei immuntherapie von autoimmunkrankheit
Taneja et al. HLA class II transgenic mice as models of human diseases
TR199802082T2 (xx) Otoantigen ve otoim�n hastal�klar�n im�noterapisinde kullan�lmak i�in otoantigen yap�sal olarak ili�kili proteinler.
JP3386614B2 (ja) 抗原特異的活性化ｔリンパ球、その検出及び使用
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
NZ332427A (en) Peptides suitable for use in antigen specific immunosuppressive therapy
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
Germain The second class story.
KR960705038A (ko) 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
DE69517521D1 (de) Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
DE69433115D1 (de) Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
DE69940927D1 (de) PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDEr AKTIVITÄT
ATE185151T1 (de) Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten
CA2270877A1 (en) Peptide-based immunotherapeutic agent
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
DE69529920D1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
Elves Immunology of cartilage
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
Zhang et al. Anti‐T‐cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin‐specific T cells
Myers et al. Immunogenicity of recombinant type IX collagen in murine collagen‐induced arthritis
Buus et al. The Interaction between MHC Class II Molecules and Immunogenic Peptides
Schwarzfischer et al. The HLA system Red cell antigens and their molecular basis Monoclonal antibodies in blood group serology Serum protein systems Biostatistics and computerisation
Kennedy THE ROLE OF THE RT6 ALLOANTIGEN IN THE INDUCTION AND REGULATION OF TUBERCULIN DELAYED HYPERSENSITIVITY IN RATS (T-LYMPHOCYTES, SUBPOPULATIONS)
EP1986011A3 (de) Durch eine CD4+-T-Lymphozyten fördernde Krankheit erkannte Peptidepitope

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee